Open AccessGraphene Nanoflake Antibody Conjugates for Multimodal Imaging of Tumors
Author(s) -
Lamb Jennifer,
Šimaitis Joris,
Halukeerthi Siriney O.,
Salzmann Christoph G.,
Holland Jason P.
Publication year - 2021
Publication title -
advanced nanobiomed research
Language(s) - English
Resource type - Journals
ISSN - 2699-9307
DOI - 10.1002/anbr.202100009
Subject(s) - conjugate , fluorophore , positron emission tomography , conjugated system , monoclonal antibody , molecular imaging , materials science , chelation , trastuzumab , fluorescence , pharmacokinetics , chemistry , in vivo , antibody , cancer , nuclear medicine , medicine , pharmacology , polymer , mathematics , mathematical analysis , composite material , biology , microbiology and biotechnology , quantum mechanics , breast cancer , metallurgy , immunology , physics
Graphene‐based materials are promising scaffolds for use in the design of tailored‐made nanomedicines. Herein, the synthesis and characterization of a series of multifunctional carboxylated graphene nanoflakes (GNFs) conjugated to monoclonal antibodies (mAbs) for tumor‐specific binding and modulation of pharmacokinetics is presented. GNF–mAb constructs are coupled to a fluorophore (4,4‐difluoro‐4‐bora‐3a,4a‐diaza‐ s ‐indacene [BODIPY]) for applications in optical imaging, a paramagnetic Gd 3+ complex, [GdDOTAGA(H 2 O)] − , and the hexadentate chelate desferrioxamine B (DFO) for radiolabeling with 89 Zr 4+ ( t 1/2 = 78.41 h) ions and applications in dual‐modality positron emission tomography/magnetic resonance imaging (PET/MRI). Experimental properties of [ 89 Zr]GdDOTAGA–ZrDFO–GNF–trastuzumab are tested in extensive chemical, spectroscopic, radiochemical, and cellular assays in vitro, and assessment of the pharmacokinetics by PET imaging in mice bearing a human ovarian cancer model illustrates the potential of using GNF–mAbs to develop multifunctional PET/MRI probes.